MENU ▼
Read by QxMD icon Read
search
OPEN IN READ APP
JOURNAL ARTICLE

Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer

J Podoba
Bratislavské Lekárske Listy 2010, 111 (1): 38-40
20429310

BACKGROUND: Despite very good prognosis patients with previously treated well-differentiated thyroid cancer (DTC) require lifelong monitoring for recurrent disease. Apart from neck ultrasonography (USG) two diagnostic tests play a central role in follow-up of these patients: radioiodine whole body scanning and serum thyroglobulin (Tg) measurement. The diagnostic value of both tests is most accurate during thyroid stimulating hormone (TSH) stimulation. Temporary discontinuation of thyroid hormone therapy was previously the sole effective approach for TSH-stimulated testing. However, hormone withdrawal was associated with the morbidity of severe hypothyroidism. The introduction of recombinant human TSH (rhTSH)-stimulated testing offers an alternative way. Recent clinical trials have shown that measurement of the rhTSH-stimulated serum Tg concentration (rhTSH-Tg) alone is the most sensitive way to detect residual or recurrent thyroid cancer.

OBJECTIVES: The aim of the study was to investigate rhTSH-Tg in patients considered to be cured with already finished radioiodine treatment 1-3 years ago (routine follow-up) and in patients more years after radioiodine therapy with a new indefinite (mild) suspicion for DTC recurrence and to report the first experience with this diagnostic procedure in Slovakia.

PATIENTS AND METHODS: RhTSH-Tg was examined in 84 patients (72 women and 12 men) clinically free of disease, 1-3 years after finishing radioiodine therapy. Second group consisted of 4 patients (2 women and 2 men) 5, 9, 12 and 38 years after 1311 treatment with a mild suspicion of DTC recurrence.

RESULTS: RhTSH testing was well tolerated. No adverse events were detected. In the first group clinically free of disease undetectable rhTSH-Tg (< 0.2 ng/ml) was found in 77 patients (91.7%), Tg above diagnostic cutoff (> 2 ng/ml) in 4 patients (4.8%) and Tg in the range 0.6-2 ng/ml in 3 cases (3.6%). In all patients of second group previous indefinite suspicion of DTC recurrence was confirmed by the rhTSH-Tg rise (2.9-7.3 ng/ml).

CONCLUSION: In accordance with the literature rhTSH-Tg concentration in combination with neck USG has the highests sensitivity and negative predictive value in detecting residual or recurrent DTC (Tab. 1, Fig. 1, Ref. 14). Full Text (Free, PDF) www.bmj.sk.

Comments

You need to log in or sign up for an account to be able to comment.

No comments yet, be the first to post one!

Related Papers

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read
20429310
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"